Clinic Research Of "Jiawei Siqi Decoction" On The Minor And Major Depression Disorder After Cerebral Stroke(PSD)

Purpose: The effectiveness and safety of “Jiawei Siqi Decoction” on the minor and majordepression disorder after cerebral stroke (PSD) is observed through the research on thepathogenesis of PSD.Method:80samples of PSD patients in accordance with the inclusion criteria arerandomly divided into two groups: the treatment group (40samples), and the control group(40samples). All samples are treated by standard treatment for Primary disease andcerebrovascular, and on top of that, the treatment group is treated by Herbal medicine “JiaweiSiqi Decoction”,1does/day, while the control group is treated by “Flupentixol and MelitracenTablets”,1tablet/day, taken30mins after breakfast. A course of treatment is8weeks. Fourscales are taken for the assessment for pretreatment, week4and8after stroke onset. Thescales are Hamilton depression scale (HAMD scale) for the assessment the depression ofpatients and the improvement of patients; Modified Edinberg-Scandinavian Stroke scale forthe assessment the neurological function defects; The doctor of Chinese herbal medicinediagnosis and treatment of post stroke depression symptoms rating scale for the assessment ofthe changes of symptoms; Treatment Emergent Symptoms Scale (TESS) for the detection ofadverse drug reaction. The effect and adverse drug reaction of the herbal medicine isevaluated through the assessment of the four scales and the statistical analysis of the testresults.Results: the treatment group and control group are randomly classified, age, gender, andthe difference among the pretreatment’s Hamilton depression scale, Modified Edinberg-Scandinavian Stroke scale of the neurological function defects, and the doctor of Chineseherbal medicine diagnosis and treatment of post stroke depression symptoms rating scale arenot statistically significant, and comparable. The analysis by SPSS15.0software shows that1)By Reduction Rate Calculation, comparing the scales of post-treatment and that of pretreatments, for both groups, the HAMD scale is statistically decreased; SSSN scale isstatistically increased; The doctor of Chinese herbal medicine diagnosis and treatment of poststroke depression symptoms rating scale is statistically decreased.2) The difference betweenpost-treatment HAMD scales of two groups is not statistically significance. The differencebetween post-treatment SSSN scales of two groups is statistically significance. The improvement on neurological function defects of treatment group is better than that of controlgroup. The difference between post-treatment “the doctor of Chinese herbal medicinediagnosis and treatment of post stroke depression symptoms rating scale” of two groups isstatistically significance, and the improvement of the treatment group is better than that of thecontrol group. The comparison of the TESS for the detection of adverse drug reactionbetween two groups shows that the reaction of the treatment group is statistically lower thanthat of the control group.Conclusion: Clinic trials prove that “Jiawei Siqi Decoction” can decrease the symptom ofminor and major depression disorder patients after cerebral stroke. Comparing with“Flupentixol and Melitracen Tablets” for the control group, it shows similar efficacy fordecrease depression symptom, while it is significantly better on improving neurologicalfunction defects. Therefore, according to the study,“Jiawei Siqi Decoction” is as clinicaleffective and safe as “Flupentixol and Melitracen Tablets” and worth the promotion and use.